Biogen (BIIB) revenue: $9.9B
Biogen reported $9.9B of revenue for the year ended Dec 31, 2025, up 2.2% from $9.7B a year earlier.
From Biogen's filings with the SEC · Read the filing · BIIB stock page
Biogen revenue by year
#433 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $9.9B | +2% |
| Dec 31, 2024 | $9.7B | -2% |
| Dec 31, 2023 | $9.8B | -3% |
| Dec 31, 2022 | $10.2B | -7% |
| Dec 31, 2021 | $11B | – |
Revenue of similar companies
Companies in the same industry as Biogen, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Amgen | $36.8B | Dec 31, 2025 |
| Gilead Sciences | $29.4B | Dec 31, 2025 |
| Biogen | $9.9B | Dec 31, 2025 |
| Neurocrine Biosciences | $2.9B | Dec 31, 2025 |
| Exelixis | $2.3B | Jan 2, 2026 |
| Qiagen | $2.1B | Dec 31, 2025 |
| Moderna | $1.9B | Dec 31, 2025 |
Questions and answers
What is Biogen's revenue?
Biogen reported $9.9B of revenue for the year ended Dec 31, 2025, up 2.2% from $9.7B a year earlier.
Numbers as reported in Biogen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology